Cabozantinib for the treatment of renal cell carcinoma.

about

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma

P2860

Q49887893-8A2D0F37-4849-4751-84D0-419FDE0B8241 Q52661758-873DFB65-EEAA-4E5B-9D95-65E7BA3CC7CC Q57481747-B29358AD-3CA9-4361-8A97-9D60F3F467F3

P2860

Cabozantinib for the treatment of renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q39005403

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cabozantinib for the treatment of renal cell carcinoma.

@en

Cabozantinib for the treatment of renal cell carcinoma.

@nl

type

Item

label

Cabozantinib for the treatment of renal cell carcinoma.

@en

Cabozantinib for the treatment of renal cell carcinoma.

@nl

prefLabel

Cabozantinib for the treatment of renal cell carcinoma.

@en

Cabozantinib for the treatment of renal cell carcinoma.

@nl

P1476

Cabozantinib for the treatment of renal cell carcinoma.

@en

P2093

Julie C Lougheed

http://www.w3.org/2001/XMLSchema#string

Laurence Albiges

http://www.w3.org/2001/XMLSchema#string

P2860

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

Cabozantinib in progressive medullary thyroid cancer.

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

P304

2499-2504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2016.1258059

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laurence Albiges

Bernard Escudier

P577

2016-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27835047

http://www.w3.org/2001/XMLSchema#string

Cabozantinib for the treatment of renal cell carcinoma.

about

P2860

P2860

Cabozantinib for the treatment of renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698